CJC-1295 vs Modified GRF 1-29

CJC-1295 vs Modified GRF 1-29 is mainly a DAC question: CJC-1295 usually means the long-acting, albumin-binding DAC form, while Modified GRF 1-29 is the short-acting no-DAC form. Choose by goal—steadier GH and IGF-1 elevation favors CJC-1295; pulse-like signaling favors Mod GRF 1-29—but no trial has compared them directly.

Are CJC-1295 and Mod GRF 1-29 the same peptide?

CJC-1295 and Mod GRF 1-29 share the same modified GHRH(1-29) base, but only the long-acting version carries DAC. GHRH means growth-hormone-releasing hormone, the signal that tells the pituitary to release growth hormone. Four amino-acid substitutions help both forms resist rapid enzyme breakdown. DAC adds an albumin-binding component that changes how long that signal stays active.

The naming is the messy part. CJC-1295 with DAC is commonly shortened to “CJC-1295.” Mod GRF 1-29 is commonly sold as “CJC-1295 without DAC” or “cjc-1295 no dac.” A label that says only CJC-1295 leaves the most useful fact unanswered. Check whether DAC is actually present; the acronym is doing more work than the brand name.

What does DAC change?

CJC-1295 with DAC stays in circulation for days because DAC binds the peptide to albumin, a large blood protein that acts like a slow-moving carrier. Mod GRF 1-29 lacks that carrier connection and clears on the order of minutes. The comparison is therefore long exposure versus short exposure, not two unrelated growth-hormone secretagogues.

The CJC-1295 human trial measured the long-acting form. After a single subcutaneous injection, growth hormone remained elevated for about six days and IGF-1 for roughly 11 days. The CJC-1295 profile describes the DAC half-life as roughly one week. Mod GRF 1-29 is intended to be brief, but no published human trial has measured its exact pulse at the doses reported outside research.

Which form better preserves natural GH pulses?

Mod GRF 1-29 better fits the goal of short, pulse-like signaling because the no-DAC peptide clears quickly instead of holding the GHRH receptor signal open for days. CJC-1295 with DAC better fits the different goal of sustained GH and IGF-1 elevation. “More natural” describes the timing pattern here; it does not prove a better health or physique result.

Growth hormone is normally released in episodes rather than as a flat stream. Mod GRF 1-29 acts more like a brief doorbell press on the pituitary. DAC CJC-1295 keeps a finger on that bell much longer. This is the practical center of cjc-1295 dac vs mod grf: pulse shape and exposure. Neither timing strategy has been shown in a direct trial to build more muscle, reduce more fat, improve recovery, or produce fewer harms.

How often are the two forms used?

CJC-1295 with DAC is associated with less-frequent administration because its albumin binding extends exposure, while Mod GRF 1-29 is reported more often because it clears quickly. The controlled CJC-1295 study used single, weight-based subcutaneous injections. No validated human schedule exists for Mod GRF 1-29, so community frequency should not be mistaken for clinical dosing evidence.

That distinction matters when comparing cjc 1295 with or without dac. A longer interval does not automatically mean safer or more effective; it means the signal lasts longer. A shorter interval does not establish superior pulse control in people; it means repeated exposure would be needed to reproduce repeated pulses. The profiles report no recommended dose for either compound, and this comparison does not turn reported use into a personal protocol.

Which option has stronger human evidence?

CJC-1295 with DAC has stronger direct human evidence for raising GH and IGF-1, while Mod GRF 1-29 remains a mechanistic hypothesis with a None-in-humans flag for its claimed outcomes. The DAC trial was randomized, double-blind, and placebo-controlled. Mod GRF 1-29 has receptor logic and related-analog evidence, but no published trial of the exact peptide.

The limit is just as important as the advantage. CJC-1295’s trial measured hormone levels, not muscle gain, fat loss, sleep, skin changes, or recovery. A Phase 2 CJC-1295 study aimed at visceral fat was terminated and produced no answer. No trial has compared mod grf 1-29 vs cjc-1295 directly; this page weighs separate pharmacology and evidence instead. The useful evidence lesson is narrow: DAC CJC-1295 has demonstrated prolonged hormone elevation, while downstream outcomes for both forms remain unsettled. See the site’s evidence-grading guide for how those labels differ.

Do the risks and legal status differ?

CJC-1295 and Mod GRF 1-29 share the broad uncertainties of unapproved GH-releasing research peptides, but the safety record is thinner for Mod GRF 1-29 specifically. Both are research-use-only in the United States as of 2026, neither appears as an approved product in Drugs@FDA, and both are prohibited at all times in sport under WADA S2.

CJC-1295’s early human trial reported injection-site reactions and facial flushing. GH-raising compounds can also bring water retention, joint discomfort, tingling in the hands, and reduced insulin sensitivity. Mod GRF 1-29’s profile borrows much of its safety context from sermorelin and the wider secretagogue class because direct human data are missing. Shorter exposure is not proof of lower risk. Research-chemical purity, dose accuracy, and sterility add uncertainty to both; the dated overview is on the regulatory-status hub.

Which one fits which goal?

CJC-1295 with DAC fits sustained hormone elevation and the preference for direct human pharmacology data; Mod GRF 1-29 fits brief, pulse-like signaling. Neither wins every category, and neither has direct human proof for the body-composition or recovery outcomes that drive much of the interest.

For steady GH elevation, the DAC form is the evidence-backed pick because prolonged GH and IGF-1 elevation was measured in people. For natural-style pulses, Mod GRF 1-29 is the pharmacologic fit because it clears in minutes. For certainty about muscle gain, fat loss, or long-term safety, neither compound has earned a confident pick. The answer to cjc-1295 vs mod grf 1-29 changes with the goal—and with whether the vial actually contains DAC.